ReviewPsychopharmacology2018
Progress and promise for the MDMA drug development program.
Review in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- MDMA and memory, addiction, and depression: dose-effect analysis.Psychopharmacology · 2022Pooled it
- Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.Journal of traumatic stress · 2021Trial
- MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.Scientific reports · 2020Trial
- Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.Psychopharmacology · 2020Trial
- Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.Journal of traumatic stress · 2020Trial
- Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder.Focus (American Psychiatric Publishing) · 2023Review
- Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.World journal of psychiatry · 2023Review
- Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation.Psychopharmacology · 2022Article
- Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.Journal of palliative medicine · 2022Article
- The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.Journal of midwifery & women's health · 2022Review
- Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder.Frontiers in psychiatry · 2022Article
- Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems.Frontiers in psychiatry · 2021Article
- The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness.Frontiers in psychiatry · 2021Article
- MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn't.Annals of general psychiatry · 2020Review
- Distinct neural mechanisms for the prosocial and rewarding properties of MDMA.Science translational medicine · 2019Article
- Using CaPsychopharmacology · 2019Review
- Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.Frontiers in psychiatry · 2019Review
- Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.ACS chemical neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs that might increase the effectiveness of psychotherapy is a logical avenue of investigation. The most promising drug studied as a catalyst to psychotherapy for PTSD thus far is 3,4-methylenedioxymethamphetamine (MDMA), commonly known as the recreational drug "Ecstasy." MDMA stimulates the release of hormones and neurochemicals that affect key brain areas for emotion and memory processing. A series of recently completed phase 2 clinical trials of MDMA-assisted psychotherapy for treatment of PTSD show favorable safety outcomes and large effect sizes that warrant expansion into multi-site phase 3 trials, set to commence in 2018. The nonprofit sponsor of the MDMA drug development program, the Multidisciplinary Association for Psychedelic Studies (MAPS), is supporting these trials to explore whether MDMA, administered on only a few occasions, can increase the effectiveness of psychotherapy. Brain imaging techniques and animal models of fear extinction are elucidating neural mechanisms underlying the robust effects of MDMA on psychological processing; however, much remains to be learned about the complexities of MDMA effects as well as the complexities of PTSD itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.